Skip to main content
Top
Published in: BMC Ophthalmology 1/2014

Open Access 01-12-2014 | Research article

Relationship between the area of isopters and Vigabatrin dosage during two years of observation

Authors: Katarzyna Nowomiejska, Marian Jedrych, Agnieszka Brzozowska, Konrad Rejdak, Tomasz Zarnowski, Michael J Koss, Katarzyna Ksiazek, Piotr Ksiazek, Ryszard Maciejewski, Anselm G Juenemann, Ulrich Schiefer, Robert Rejdak

Published in: BMC Ophthalmology | Issue 1/2014

Login to get access

Abstract

Background

The aim of the study was to evaluate the relationship between the area of isopters obtained using semi-automated kinetic perimetry (SKP) and Vigabatrin dosage in epilepsy patients with pretreatment baseline examination during 2-years of the follow-up.

Methods

29 epilepsy patients were included into the study, but 15 individuals were excluded due to cognitive impairment, intracranial pathologies or eye diseases. Finally, 14 patients were examined with SKP before VGB treatment and after 6, 12, 18, and 24 months. Reaction time (RT)-corrected areas of three isopters (III4e, I4e and I2e) were measured for each of five examinations and compared intra-individually during 2-years period. Additionally, six epilepsy patients on other antiepileptic drugs were examined five times with SKP as a control.

Results

There was a significant decrease of I2e, I4e and III4e isopters’ area during the follow-up of two years. Correlation was found between the I2e isopter’s area and both cumulative dose and mean daily dose of VGB. With increasing RT, there was decreasing of all isopters’ area in patients receiving VGB. In epilepsy patients who were not receiving VGB, there were no significance differences in isopters’ area during follow-up.

Conclusion

There was attenuation of area of III4e, I4e and I2e isopters obtained with SKP during a period of 2 years. RT, the cumulative dose and the mean daily dose of VGB influenced isopters' area obtained with SKP.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schechter PJ, Tranier Y, Jung MJ, Boehlen P: Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol. 1977, 45: 319-328. 10.1016/0014-2999(77)90270-9.CrossRefPubMed Schechter PJ, Tranier Y, Jung MJ, Boehlen P: Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol. 1977, 45: 319-328. 10.1016/0014-2999(77)90270-9.CrossRefPubMed
3.
go back to reference Newman WD, Tocher K, Acheson JF: Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye. 2002, 16: 567-571. 10.1038/sj.eye.6700168.CrossRefPubMed Newman WD, Tocher K, Acheson JF: Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye. 2002, 16: 567-571. 10.1038/sj.eye.6700168.CrossRefPubMed
4.
go back to reference Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TT, Stilma JS: Visual field loss associated with Vigabatrin: quantification and relation to dosage. Epilepsia. 2001, 42 (2): 262-267.CrossRefPubMed Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TT, Stilma JS: Visual field loss associated with Vigabatrin: quantification and relation to dosage. Epilepsia. 2001, 42 (2): 262-267.CrossRefPubMed
5.
go back to reference Fledelius HC: Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand. 2003, 81 (1): 41-46. 10.1034/j.1600-0420.2003.00023.x.CrossRefPubMed Fledelius HC: Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand. 2003, 81 (1): 41-46. 10.1034/j.1600-0420.2003.00023.x.CrossRefPubMed
6.
go back to reference Midelfart A, Midelfart E, Brodtkorb E: Visual field defects in patients taking vigabatrin. Acta Ophthalmol Scand. 2000, 78: 580-584. 10.1034/j.1600-0420.2000.078005580.x.CrossRefPubMed Midelfart A, Midelfart E, Brodtkorb E: Visual field defects in patients taking vigabatrin. Acta Ophthalmol Scand. 2000, 78: 580-584. 10.1034/j.1600-0420.2000.078005580.x.CrossRefPubMed
7.
go back to reference Schmidt T, Rüther K, Jokiel K, Pfeiffer S, Tiel-Wilck K, Schmitz B: Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol. 2002, 249: 1066-1071. 10.1007/s00415-002-0789-y.CrossRefPubMed Schmidt T, Rüther K, Jokiel K, Pfeiffer S, Tiel-Wilck K, Schmitz B: Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol. 2002, 249: 1066-1071. 10.1007/s00415-002-0789-y.CrossRefPubMed
8.
go back to reference Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA: Visual function is stable in patients who continue long-term Vigabatrin therapy: implications for clinical decision making. Epilepsia. 2001, 42 (4): 525-530. 10.1046/j.1528-1157.2001.49299.x.CrossRefPubMed Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA: Visual function is stable in patients who continue long-term Vigabatrin therapy: implications for clinical decision making. Epilepsia. 2001, 42 (4): 525-530. 10.1046/j.1528-1157.2001.49299.x.CrossRefPubMed
9.
go back to reference Versino M, Viggiotti P: Reversibility of Vigabatrin induced visual field defect. Lancet. 1999, 354: 486-CrossRefPubMed Versino M, Viggiotti P: Reversibility of Vigabatrin induced visual field defect. Lancet. 1999, 354: 486-CrossRefPubMed
10.
go back to reference Hawker MJ, Astbury NJ: The ocular side effects of vigabatrin (Sabril): information and guidance for screening. Eye. 2008, 22 (9): 1097-1098. 10.1038/eye.2008.139.CrossRefPubMed Hawker MJ, Astbury NJ: The ocular side effects of vigabatrin (Sabril): information and guidance for screening. Eye. 2008, 22 (9): 1097-1098. 10.1038/eye.2008.139.CrossRefPubMed
11.
go back to reference Vonthein R, Rauscher S, Paetzold J, Nowomiejska K, Krapp E, Hermann A, Sadowski B, Chaumette C, Wild JM, Schiefer U: The normal age-corrected and reaction time-corrected isopter derived by semi-automated kinetic perimetry. Ophthalmology. 2007, 114 (6): 1065-1072. 10.1016/j.ophtha.2006.09.030.CrossRefPubMed Vonthein R, Rauscher S, Paetzold J, Nowomiejska K, Krapp E, Hermann A, Sadowski B, Chaumette C, Wild JM, Schiefer U: The normal age-corrected and reaction time-corrected isopter derived by semi-automated kinetic perimetry. Ophthalmology. 2007, 114 (6): 1065-1072. 10.1016/j.ophtha.2006.09.030.CrossRefPubMed
12.
go back to reference Nowomiejska K, Vonthein R, Paetzold J, Zagorski Z, Kardon R, Schiefer U: Comparison between semi-automated kinetic perimetry (SKP) and conventional Goldmann manual kinetic perimetry (MKP) in patients with advanced visual field loss. Ophthalmology. 2005, 112: 1343-1354. 10.1016/j.ophtha.2004.12.047.CrossRefPubMed Nowomiejska K, Vonthein R, Paetzold J, Zagorski Z, Kardon R, Schiefer U: Comparison between semi-automated kinetic perimetry (SKP) and conventional Goldmann manual kinetic perimetry (MKP) in patients with advanced visual field loss. Ophthalmology. 2005, 112: 1343-1354. 10.1016/j.ophtha.2004.12.047.CrossRefPubMed
13.
go back to reference Nowomiejska K, Rejdak R, Zagorski Z, Zarnowski T: Comparison of static automated perimetry and semi-automated kinetic perimetry in patients with bilateral visible optic nerve head drusen. Acta Ophthalmol. 2009, 87 (7): 801-805. 10.1111/j.1755-3768.2008.01364.x.CrossRefPubMed Nowomiejska K, Rejdak R, Zagorski Z, Zarnowski T: Comparison of static automated perimetry and semi-automated kinetic perimetry in patients with bilateral visible optic nerve head drusen. Acta Ophthalmol. 2009, 87 (7): 801-805. 10.1111/j.1755-3768.2008.01364.x.CrossRefPubMed
14.
go back to reference Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010, 51: 676-685. 10.1111/j.1528-1167.2010.02522.x.CrossRefPubMed Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010, 51: 676-685. 10.1111/j.1528-1167.2010.02522.x.CrossRefPubMed
15.
go back to reference Kälviäinen R, Nousiainen I, Mäntyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Sr Riekkinen P: Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999, 53: 922-10.1212/WNL.53.5.922.CrossRefPubMed Kälviäinen R, Nousiainen I, Mäntyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Sr Riekkinen P: Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999, 53: 922-10.1212/WNL.53.5.922.CrossRefPubMed
16.
go back to reference Wild JM, Martinez C, Reinshagen G, Harding GF: Characteristics of a unique visual field defect attributed to Vigabatrin. Epilepsia. 1999, 40 (12): 1784-1794. 10.1111/j.1528-1157.1999.tb01599.x.CrossRefPubMed Wild JM, Martinez C, Reinshagen G, Harding GF: Characteristics of a unique visual field defect attributed to Vigabatrin. Epilepsia. 1999, 40 (12): 1784-1794. 10.1111/j.1528-1157.1999.tb01599.x.CrossRefPubMed
17.
go back to reference Vanhatalo S, Nousiainen I, Eriksson K, Rantala H, Vainionpää L, Mustonen K, Aärimaa T, Alen R, Aine MR, Byring R, Hirvasniemi A, Nuutila A, Walden T, Ritanen-Mohammed UM, Karttunen-Lewandowski P, Pohjola LM, Kaksonen S, Jurvelin P, Granström ML: Visual field constriction in 91 Finnish children treated with Vigabatrin. Epilepsia. 2002, 43 (7): 748-756. 10.1046/j.1528-1157.2002.17801.x.CrossRefPubMed Vanhatalo S, Nousiainen I, Eriksson K, Rantala H, Vainionpää L, Mustonen K, Aärimaa T, Alen R, Aine MR, Byring R, Hirvasniemi A, Nuutila A, Walden T, Ritanen-Mohammed UM, Karttunen-Lewandowski P, Pohjola LM, Kaksonen S, Jurvelin P, Granström ML: Visual field constriction in 91 Finnish children treated with Vigabatrin. Epilepsia. 2002, 43 (7): 748-756. 10.1046/j.1528-1157.2002.17801.x.CrossRefPubMed
18.
go back to reference Sergott RC, Westall CA: Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand Suppl. 2011, 192: 48-56.CrossRefPubMed Sergott RC, Westall CA: Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand Suppl. 2011, 192: 48-56.CrossRefPubMed
19.
go back to reference Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N: Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia. 2006, 47 (2): 311-317. 10.1111/j.1528-1167.2006.00422.x.CrossRefPubMed Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N: Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia. 2006, 47 (2): 311-317. 10.1111/j.1528-1167.2006.00422.x.CrossRefPubMed
20.
go back to reference Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE: Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci. 2006, 47 (3): 917-924. 10.1167/iovs.05-0854.CrossRefPubMed Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE: Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci. 2006, 47 (3): 917-924. 10.1167/iovs.05-0854.CrossRefPubMed
21.
go back to reference Moseng L, Sæter M, Mørch-Johnsen GH, Hoff JM, Gajda A, Brodtkorb E, Midelfart A: Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol. 2011, 89 (5): 452-458. 10.1111/j.1755-3768.2010.02077.x.CrossRefPubMed Moseng L, Sæter M, Mørch-Johnsen GH, Hoff JM, Gajda A, Brodtkorb E, Midelfart A: Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol. 2011, 89 (5): 452-458. 10.1111/j.1755-3768.2010.02077.x.CrossRefPubMed
22.
go back to reference Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Rüther K: Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol. 2002, 249 (4): 469-475. 10.1007/s004150200041.CrossRefPubMed Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Rüther K: Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol. 2002, 249 (4): 469-475. 10.1007/s004150200041.CrossRefPubMed
23.
go back to reference Clayton LM, Stern WM, Newman WD, Sander JW, Acheson J, Sisodiya SM: Evolution of visual field loss over ten years in individuals taking vigabatrin. Epilepsy Res. 2013, 105 (3): 262-271. 10.1016/j.eplepsyres.2013.02.014.CrossRefPubMed Clayton LM, Stern WM, Newman WD, Sander JW, Acheson J, Sisodiya SM: Evolution of visual field loss over ten years in individuals taking vigabatrin. Epilepsy Res. 2013, 105 (3): 262-271. 10.1016/j.eplepsyres.2013.02.014.CrossRefPubMed
24.
go back to reference Frisén L: Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand. 2004, 82 (1): 54-58. 10.1046/j.1600-0420.2003.00184.x.CrossRefPubMed Frisén L: Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand. 2004, 82 (1): 54-58. 10.1046/j.1600-0420.2003.00184.x.CrossRefPubMed
25.
go back to reference Conway M, Cubbidge RP, Hosking SL: Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008, 49 (1): 108-116. 10.1111/j.1528-1167.2007.01249.x.CrossRefPubMed Conway M, Cubbidge RP, Hosking SL: Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008, 49 (1): 108-116. 10.1111/j.1528-1167.2007.01249.x.CrossRefPubMed
26.
go back to reference Besch D, Schiefer U, Eter N, Burth R, Elger CE, Spitznas M, Dietz K: Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field. Graefes Arch Clin Exp Ophthalmol. 2011, 249 (9): 1333-1343. 10.1007/s00417-011-1625-9.CrossRefPubMed Besch D, Schiefer U, Eter N, Burth R, Elger CE, Spitznas M, Dietz K: Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field. Graefes Arch Clin Exp Ophthalmol. 2011, 249 (9): 1333-1343. 10.1007/s00417-011-1625-9.CrossRefPubMed
27.
go back to reference Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D: Symptomatic and asymptomatic visual loss in patients taking Vigabatrin. Ophthalmology. 1999, 106: 1792-1798. 10.1016/S0161-6420(99)90345-7.CrossRefPubMed Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D: Symptomatic and asymptomatic visual loss in patients taking Vigabatrin. Ophthalmology. 1999, 106: 1792-1798. 10.1016/S0161-6420(99)90345-7.CrossRefPubMed
28.
go back to reference Lynn JR: Examination of the visual field in glaucoma. Invest Ophthalmol. 1969, 8 (1): 76-84.PubMed Lynn JR: Examination of the visual field in glaucoma. Invest Ophthalmol. 1969, 8 (1): 76-84.PubMed
29.
go back to reference Nowomiejska K, Vonthein R, Paetzold J, Zagorski Z, Kardon R, Schiefer U: Reaction time during semi-automated kinetic perimetry (SKP) in patients with advanced visual field loss. Acta Ophthalmol. 2010, 88 (1): 65-69. 10.1111/j.1755-3768.2008.01407.x.CrossRefPubMed Nowomiejska K, Vonthein R, Paetzold J, Zagorski Z, Kardon R, Schiefer U: Reaction time during semi-automated kinetic perimetry (SKP) in patients with advanced visual field loss. Acta Ophthalmol. 2010, 88 (1): 65-69. 10.1111/j.1755-3768.2008.01407.x.CrossRefPubMed
30.
go back to reference Naili F, Boucart M, Derambure P, Arndt C: Visual impairment at large eccentricity in participants treated by vigabatrin: visual, attentional or recognition deficit?. Epilepsy Res. 2009, 87 (2–3): 213-222.CrossRefPubMed Naili F, Boucart M, Derambure P, Arndt C: Visual impairment at large eccentricity in participants treated by vigabatrin: visual, attentional or recognition deficit?. Epilepsy Res. 2009, 87 (2–3): 213-222.CrossRefPubMed
31.
go back to reference Nowomiejska K, Brzozowska A, Zarnowski T, Rejdak R, Weleber RG, Schiefer U: Variability of isopter position and fatigue during semi-automated kinetic perimetry. Ophthalmologica. 2012, 227 (3): 166-172. 10.1159/000333821.CrossRefPubMed Nowomiejska K, Brzozowska A, Zarnowski T, Rejdak R, Weleber RG, Schiefer U: Variability of isopter position and fatigue during semi-automated kinetic perimetry. Ophthalmologica. 2012, 227 (3): 166-172. 10.1159/000333821.CrossRefPubMed
Metadata
Title
Relationship between the area of isopters and Vigabatrin dosage during two years of observation
Authors
Katarzyna Nowomiejska
Marian Jedrych
Agnieszka Brzozowska
Konrad Rejdak
Tomasz Zarnowski
Michael J Koss
Katarzyna Ksiazek
Piotr Ksiazek
Ryszard Maciejewski
Anselm G Juenemann
Ulrich Schiefer
Robert Rejdak
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2014
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/1471-2415-14-56

Other articles of this Issue 1/2014

BMC Ophthalmology 1/2014 Go to the issue

Reviewer acknowledgement

Reviewer acknowledgement 2013